Filing Details
- Accession Number:
- 0001689375-24-000054
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-10 16:33:34
- Reporting Period:
- 2024-09-06
- Accepted Time:
- 2024-09-10 16:33:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1689375 | Entrada Therapeutics Inc. | TRDA | Pharmaceutical Preparations (2834) | 813983399 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1873392 | J Nathan Dowden | C/O Entrada Therapeutics, Inc. One Design Center Place, Suite 17-500 Boston MA 02210 | President & Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-09-06 | 399 | $15.19 | 127,900 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-09-09 | 1,904 | $15.07 | 125,996 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.07 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.